A retrospective study investigating the efficacy and toxicity of anlotinib with or without PD-1 blockades in the treatment of advanced primary HCC in real-world study
Latest Information Update: 03 Mar 2022
At a glance
- Drugs Catequentinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 03 Mar 2022 New trial record
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium